NCT03417544View on ClinicalTrials.gov

Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

May 21, 2018

Primary Completion Date

May 20, 2020

Study Completion Date

December 31, 2025

Conditions
HER2-positive Metastatic Breast CancerCentral Nervous System Metastases
Interventions
DRUG

ATEZOLIZUMAB

(IV) every 3 weeks

DRUG

PERTUZUMAB

Loading dose, followed every 3 weeks thereafter by a predetermined dose in the protocol via IV

DRUG

TRASTUZUMAB

Predetermined dose per protocol via IV, weekly for 24 weeks and after every 3 weeks

Trial Locations (2)

60611

Northwestern University, Chicago

02215

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Nancy Lin, MD

OTHER